Allan May, co-founder and Chairman of Life Science Angels, invests exclusively in early-stage life science companies. See sector focus and contact routes.
Allan May, co-founder and Chairman of Life Science Angels, invests exclusively in early-stage life science companies across four sectors: biotech, medical devices, diagnostics, and digital health (including genomics and mobile health). The group has deployed over $75 million into 70+ portfolio companies, with no specific check size publicly disclosed for individual deals. His distinctive thesis focuses on supporting both “wet” science (biology, genomics, tools) and “dry” science (devices, diagnostics, catheters), leveraging a network of industry veterans to identify innovations addressing unmet medical needs. Notable portfolio exits include eValve (acquired by Abbott), Nanostim (acquired by St. Jude Medical), CyberHeart, Crux, and StimWave.
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in Sunnyvale.
Investors like Allan May · Full investor directory · Investor access · Company funding database